Tags

Type your tag names separated by a space and hit enter

Current management options for hereditary angioedema.
Curr Allergy Asthma Rep 2012; 12(4):273-80CA

Abstract

The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor have been approved. Fresh frozen plasma is also available for treating acute attacks. Short-term prophylactic treatment focuses on C1-INH and attenuated androgens. Long-term prophylactic treatments include attenuated androgens such as danazol, stanozolol, and oxandrolone, antifibrinolytics, and a plasma-derived C1-INH concentrate. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are permitted for self-administration and home therapy. The number of management options has increased considerably within the last few years, thus helping to diminish the burden of HAE.

Authors+Show Affiliations

Department of Dermatology, Johannes Gutenberg University, Mainz, Germany. bork@hautklinik.klinik.uni-mainz.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22729959

Citation

Bork, Konrad. "Current Management Options for Hereditary Angioedema." Current Allergy and Asthma Reports, vol. 12, no. 4, 2012, pp. 273-80.
Bork K. Current management options for hereditary angioedema. Curr Allergy Asthma Rep. 2012;12(4):273-80.
Bork, K. (2012). Current management options for hereditary angioedema. Current Allergy and Asthma Reports, 12(4), pp. 273-80. doi:10.1007/s11882-012-0273-4.
Bork K. Current Management Options for Hereditary Angioedema. Curr Allergy Asthma Rep. 2012;12(4):273-80. PubMed PMID: 22729959.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current management options for hereditary angioedema. A1 - Bork,Konrad, PY - 2012/6/26/entrez PY - 2012/6/26/pubmed PY - 2013/4/11/medline SP - 273 EP - 80 JF - Current allergy and asthma reports JO - Curr Allergy Asthma Rep VL - 12 IS - 4 N2 - The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor have been approved. Fresh frozen plasma is also available for treating acute attacks. Short-term prophylactic treatment focuses on C1-INH and attenuated androgens. Long-term prophylactic treatments include attenuated androgens such as danazol, stanozolol, and oxandrolone, antifibrinolytics, and a plasma-derived C1-INH concentrate. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are permitted for self-administration and home therapy. The number of management options has increased considerably within the last few years, thus helping to diminish the burden of HAE. SN - 1534-6315 UR - https://www.unboundmedicine.com/medline/citation/22729959/Current_management_options_for_hereditary_angioedema_ L2 - https://dx.doi.org/10.1007/s11882-012-0273-4 DB - PRIME DP - Unbound Medicine ER -